GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Cyclically Adjusted PS Ratio

RGBP (Regen BioPharma) Cyclically Adjusted PS Ratio : 0.08 (As of Apr. 26, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma Cyclically Adjusted PS Ratio?

As of today (2025-04-26), Regen BioPharma's current share price is $0.054. Regen BioPharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was $0.65. Regen BioPharma's Cyclically Adjusted PS Ratio for today is 0.08.

The historical rank and industry rank for Regen BioPharma's Cyclically Adjusted PS Ratio or its related term are showing as below:

RGBP' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.08   Med: 0.61   Max: 4.45
Current: 0.09

During the past years, Regen BioPharma's highest Cyclically Adjusted PS Ratio was 4.45. The lowest was 0.08. And the median was 0.61.

RGBP's Cyclically Adjusted PS Ratio is ranked better than
97.04% of 507 companies
in the Biotechnology industry
Industry Median: 5 vs RGBP: 0.09

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Regen BioPharma's adjusted revenue per share data for the three months ended in Sep. 2024 was $0.006. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.65 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Regen BioPharma Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Regen BioPharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Cyclically Adjusted PS Ratio Chart

Regen BioPharma Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.23 0.16

Regen BioPharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.23 0.68 0.54 0.48 0.16

Competitive Comparison of Regen BioPharma's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Regen BioPharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Cyclically Adjusted PS Ratio falls into.


;
;

Regen BioPharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Regen BioPharma's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.054/0.65
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Regen BioPharma's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.006/133.0289*133.0289
=0.006

Current CPI (Sep. 2024) = 133.0289.

Regen BioPharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 1.255 100.392 1.663
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.543 101.861 0.709
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.598 103.349 0.770
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.488 106.317 0.611
201809 0.000 106.507 0.000
201812 0.096 105.998 0.120
201903 0.069 107.251 0.086
201906 0.237 108.070 0.292
201909 0.035 108.329 0.043
201912 0.024 108.420 0.029
202003 0.013 108.902 0.016
202006 0.013 108.767 0.016
202009 0.013 109.815 0.016
202012 0.011 109.897 0.013
202103 0.008 111.754 0.010
202106 0.012 114.631 0.014
202109 0.011 115.734 0.013
202112 0.010 117.630 0.011
202203 0.010 121.301 0.011
202206 0.009 125.017 0.010
202209 0.010 125.227 0.011
202212 0.009 125.222 0.010
202303 0.018 127.348 0.019
202306 0.009 128.729 0.009
202309 0.007 129.860 0.007
202312 0.008 129.419 0.008
202403 0.007 131.776 0.007
202406 0.007 132.554 0.007
202409 0.006 133.029 0.006

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regen BioPharma  (OTCPK:RGBP) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Regen BioPharma Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regen BioPharma Business Description

Traded in Other Exchanges
Address
4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.